BioPharmX (BPMX) Reports Q1 Loss of $0.08/Share, Explores Funding Alternatives

BioPharmX (NYSE: BPMX) reported Q1 EPS of ($0.08), versus ($0.17) reported last year.

The company expects the phase 3 program to begin later this year and is exploring a variety of funding alternatives, including both dilutive and non-dilutive financing options and strategic partnerships.

For earnings history and earnings-related data on BioPharmX (BPMX) click here.

You May Also Be Interested In

• Phillip Securities Reiterates Buy Rating on Sea Ltd. (SE)
• Jasper Therapeutics (JSPR) Tops Q2 EPS by 18c
• Greenlane Holdings Inc. (GNLN) reported Q2 result